|
46
|
| 128 |
Streptozocin
|
|
increases_quantity of
|
NO
|
in serum; under hyperglycemic condition
|
| 132 |
Arjunolic acid
|
|
decreases_quantity of
|
NO
|
in serum; in STZ treated rats
|
|
19133311
|
Diabetes mellitus, type I
|
|
125
|
| 440 |
SNCA
|
|
increases_quantity of
|
NO
|
in mitochondria; if SNCA is overexpressed
|
|
18322646
|
Parkinson disease
|
|
310
|
| 1224 |
NO
|
|
increases_quantity of
|
FASLG
|
in wt and mutant mice
|
| 1228 |
NO
|
NOT |
affects_quantity of
|
FAS
|
in wt and mutant mice
|
| 1232 |
NO
|
|
increases_activity of
|
neuron death
|
in SOD1(G93A) or SOD1(G85R) mutant mice motoneurons
|
| 13483 |
NOS1
|
|
increases_quantity of
|
NO
|
in SOD1(G93A) or SOD1(G85R) mutant mice motoneurons
|
|
16581901
|
Amyotrophic lateral sclerosis
|
|
339
|
| 13705 |
response to oxidative stress
|
|
increases_quantity of
|
NO
|
in pilocarpine rat model
|
|
19800952
|
Status epilepticus
|
|
350
|
| 1397 |
NO
|
|
increases_activity of
|
motor neuron degeneration
|
in Fas-activated motoneurons
|
| 2455 |
NOS1
|
|
increases_quantity of
|
NO
|
in Fas-activated motoneurons
|
|
12354397
|
Amyotrophic lateral sclerosis
|
|
370
|
| 1501 |
injury by unilateral sciatic nerve avulsion
|
|
increases_quantity of
|
NO
|
|
|
16000635
|
Amyotrophic lateral sclerosis
|
|
672
|
| 3598 |
Status epilepticus
|
|
increases_quantity of
|
NO
|
in lithium-pilocarpine model
|
|
20149694
|
Status epilepticus
|
|
806
|
| 4651 |
NOS1
|
|
increases_quantity of
|
NO
|
|
| 4652 |
NO
|
|
affects_activity of
|
PDIA2
|
by nitrosylation
|
| 4653 |
NO
|
|
increases_quantity of
|
PDIA2-mod
|
|
|
16724068
|
Neurological
Amyotrophic lateral sclerosis
|
|
809
|
| 4659 |
NO
|
|
decreases_activity of
|
protein stabilization
|
|
|
16724068
|
Alzheimer disease
Parkinson disease
|
|
1,086
|
| 6887 |
PARK7
|
|
decreases_quantity of
|
NO
|
in response to LPS, via p38MAPK pathway
|
| 6892 |
Lipopolysaccharide
|
|
increases_quantity of
|
NO
|
|
| 6893 |
NOS2
|
|
increases_quantity of
|
NO
|
|
| 6894 |
PARK7
|
|
decreases_quantity of
|
NO
|
|
|
19276172
|
Parkinson disease
|
|
1,092
|
| 7226 |
NO
|
|
affects_activity of
|
Insulin resistance
|
|
| 7242 |
NO
|
|
decreases_activity of
|
AKT1
|
|
|
18053812
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,115
|
| 7168 |
NaHS
|
|
decreases_quantity of
|
NO
|
in striatum; via NF-kappaB pathway
|
|
20041858
|
Parkinson disease
|
|
1,137
|
| 7394 |
SNCA
|
|
increases_quantity of
|
NO
|
in microglia
|
| 7402 |
MMP3
|
|
affects_quantity of
|
NO
|
after stimulation with alpha-synuclein
|
| 7407 |
MMP8
|
|
affects_quantity of
|
NO
|
after stimulation with alpha-synuclein
|
| 7411 |
MMP9
|
|
affects_quantity of
|
NO
|
after stimulation with alpha-synuclein
|
|
20511551
|
Parkinson disease
|
|
1,150
|
| 7510 |
MAP3K5
|
|
increases_quantity of
|
NO
|
after induction with LPS
|
|
15864310
|
Parkinson disease
|
|
1,182
|
| 7837 |
NOS2
|
|
increases_quantity of
|
NO
|
in primary astrocyte monolayers
|
|
11754077
|
Amyotrophic lateral sclerosis
|
|
1,230
|
| 8265 |
astrocyte
|
|
decreases_quantity of
|
NO
|
in microglia
|
|
16467537
|
Parkinson disease
|
|
1,249
|
| 8454 |
microglial cell activation
|
|
increases_quantity of
|
NO
|
|
| 8455 |
NO
|
|
increases_activity of
|
neuron death
|
|
| 8456 |
astrocyte activation
|
|
increases_quantity of
|
NO
|
|
| 8457 |
NO
|
|
decreases_activity of
|
oxidative phosphorylation
|
in mitochondria
|
| 8459 |
NO
|
|
increases_quantity of
|
Glutamate
|
|
|
11517237
|
Parkinson disease
|
|
1,286
|
| 8746 |
Dextromethorphan
|
|
decreases_quantity of
|
NO
|
after induction of NO via LPS addition
|
|
12649371
|
Parkinson disease
|
|
1,310
|
| 8947 |
NO
|
|
increases_activity of
|
motor neuron degeneration
|
in mutant SOD1G85R mice
|
| 8950 |
NO
|
|
increases_quantity of
|
DPYSL3a
|
in mutant SOD1G85R mice
|
| 8951 |
NO
|
NOT |
increases_quantity of
|
DPYSL2
|
in mutant SOD1G85R mice
|
|
20071543
|
Amyotrophic lateral sclerosis
|
|
1,343
|
| 9162 |
SOD1-p.G93A
|
|
increases_quantity of
|
NO
|
in microglia; induced by LPS
|
| 9171 |
NO
|
|
affects_activity of
|
microglial cell activation
|
|
|
17555556
|
Amyotrophic lateral sclerosis
|
|
1,344
|
| 9166 |
SOD1-p.G93A
|
|
increases_quantity of
|
NO
|
in microglia/motoneuron co-cultures
|
| 9170 |
NO
|
|
increases_activity of
|
motor neuron degeneration
|
in microglia/motoneuron co-cultures
|
|
17555556
|
Amyotrophic lateral sclerosis
|
|
1,357
|
| 9277 |
NOX1
|
|
increases_quantity of
|
NO
|
in microglia; induced by LPS
|
| 9278 |
CYBB
|
|
increases_quantity of
|
NO
|
in microglia; induced by LPS
|
|
19005069
|
Amyotrophic lateral sclerosis
|
|
1,588
|
| 11457 |
innate immune response
|
|
increases_quantity of
|
NO
|
|
|
20463396
|
Alzheimer disease
Multiple sclerosis
Parkinson disease
|
|
1,598
|
| 11666 |
Lipopolysaccharide
|
|
increases_quantity of
|
NO
|
in peritoneal macrophages
|
| 11671 |
Epigallocatechin 3-gallate
|
|
decreases_quantity of
|
NO
|
in peritoneal macrophages; after LPS treatment
|
|
20511545
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,680
|
| 12547 |
PC-12 cell
|
|
increases_quantity of
|
NO
|
|
| 12552 |
NO
|
|
affects_activity of
|
mitochondrion
|
|
| 12558 |
NO
|
|
affects_activity of
|
Alzheimer disease
|
|
|
15591653
|
Alzheimer disease
|
|
1,752
|
| 13179 |
SOD1-p.G93A
|
|
increases_quantity of
|
NO
|
in motor neurons
|
|
17099894
|
Amyotrophic lateral sclerosis
|
|
1,823
|
| 13695 |
Amyloid beta peptide
|
|
affects_quantity of
|
NO
|
in AD choroid plexus; when elevated expression of Abeta
|
| 13700 |
NO
|
|
affects_activity of
|
abnormal mitochondrial physiology
|
|
| 13809 |
Alzheimer disease
|
|
increases_quantity of
|
NO
|
in choroid plexus
|
| 13810 |
APP/PS1 mouse
|
|
increases_quantity of
|
NO
|
in choroid plexus
|
|
18838197
|
Alzheimer disease
|
|
1,847
|
| 13991 |
Amyloid beta peptide
|
|
affects_quantity of
|
NO
|
|
| 13993 |
NO
|
|
affects_processing of
|
DNM1L
|
S-nitrosylation of endogenous DRP1/DNM1L
|
| 14000 |
NO
|
|
increases_activity of
|
mitochondrial fission
|
|
| 14003 |
NO
|
|
increases_activity of
|
DRP1 homodimerization
|
of DRP1 via S-nitrosylation of Cys644
|
| 14006 |
NO
|
|
increases_quantity of
|
DNM1L-SNO (homodimer)
|
homodimer formation
|
| 14009 |
NO
|
|
affects_activity of
|
GTPase
|
of DRP1-SNO via DRP1-SNO dimerization
|
|
19342591
|
Alzheimer disease
|
|
1,885
|
| 14322 |
NOS2
|
|
increases_quantity of
|
NO
|
|
| 14323 |
NOS2
|
|
increases_quantity of
|
NO
|
|
|
19178557
|
Status epilepticus
|
|
1,957
|
| 15189 |
NO
|
|
increases_activity of
|
response to oxidative stress
|
|
| 15299 |
NO
|
|
decreases_activity of
|
Oxoglutarate dehydrogenase
|
|
|
19076444
|
Alzheimer disease
|
CIDeRplus